Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.

摘要: Immunotherapies targeting the programmed cell death-1/programmed death-ligand 1 pathway have emerged as promising therapeutic strategies for lung cancer. However, expression pattern and prognostic implications of 2 death-1 in comparison with histology genetic alterations pulmonary adenocarcinomas remains unclear thus were addressed here. Programmed tumor cells quantities death-1(+) CD8(+) tumor-infiltrating lymphocytes immunohistochemically evaluated 497 resected analyzed according to clinicopathological statuses. observed 59% 64% adenocarcinomas, respectively, showed a strong positive correlation each other (P < 0.001). was higher nodal metastasis cases = 0.006), smokers 0.056), poorly differentiated tumors histologic subtypes solid micropapillary patterns There no significant difference EGFR mutation status. correlated ALK translocation =0.054) MET Meanwhile, 0.052), 0.001) ERBB2 0.013). The numbers 0.012 0.016) MET-expressing Patients expressing and/or high ratios death-1(+)/CD8(+) shorter disease-free survival Our study demonstrated that varied histology, EGFR, ALK, MET, statuses, activation may be poor factor adenocarcinomas.